1. Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport
- Author
-
Simon J. Davies, Sara N. Davison, Nicholas Topley, James Chess, Mark Lambie, Emma Elphick, Jun-Young Do, Lucy Teece, Yong-Lim Kim, and H. Bahl Lee
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Epidemiology ,medicine.medical_treatment ,030232 urology & nephrology ,Urology ,Peritonitis ,Renal function ,030204 cardiovascular system & hematology ,Q1 ,Critical Care and Intensive Care Medicine ,Icodextrin ,Peritoneal dialysis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Interquartile range ,Dialysis Solutions ,medicine ,Humans ,Prospective Studies ,Peritoneal Fibrosis ,Transplantation ,Creatinine ,Errata ,business.industry ,Biological Transport ,Original Articles ,Middle Aged ,medicine.disease ,R1 ,Confidence interval ,chemistry ,Nephrology ,Female ,Peritoneum ,business ,Peritoneal Dialysis - Abstract
Background and objectives\ud The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined the association with their use and longitudinal peritoneal solute transport rate.\ud \ud Design, setting, participants, & measurements\ud We analyzed subjects from the multinational prospective Global Fluid Study with three or more peritoneal solute transport rate measurements >2 months from the start of peritoneal dialysis. Follow-up was for 7.5 years (median, 2.3 years; interquartile range, 1.8–3.6) in biocompatible solutions and 12.8 years (median, 3.2 years; interquartile range, 1.9–4.3) for standard solutions. Using a random intercept/slopes multilevel model, we examined the association of patients using biocompatible solutions and peritoneal solute transport rate over time, adjusting for center effects, dialysate dextrose concentration, baseline dialysate IL-6 concentration, icodextrin use, residual kidney function, and peritonitis.\ud \ud Results\ud Of 366 patients, the 71 receiving biocompatible solutions throughout their time on peritoneal dialysis had a mean adjusted dialysate-to-plasma creatinine ratio of 0.67 compared with 0.72 for standard solutions (P=0.02). With duration of treatment, there was a continuous increase in peritoneal solute transport rate in patients using standard solutions (range, 2 months to 4 years). In contrast, patients using biocompatible solutions had peritoneal solute transport rates that plateaued after 2 years of therapy. These changes in peritoneal solute transport rate were independent of baseline inflammation and time-varying predictors of faster peritoneal solute transport rate. In patients suffering episodes of peritonitis while using standard solutions, there was an associated increase in peritoneal solute transport rate of 0.020 (95% confidence interval, 0.01 to 0.03) per episode, whereas in patients using biocompatible solutions, there was no change in this parameter (−0.014; 95% confidence interval, −0.03 to
- Published
- 2018
- Full Text
- View/download PDF